Department of Chemistry, Texas Christian University, Fort Worth, TX 76129, USA.
Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Biomolecules. 2019 Aug 28;9(9):421. doi: 10.3390/biom9090421.
Various glutamate urea ligands have displayed high affinities to prostate specific membrane antigen (PSMA), which is highly overexpressed in prostate and other cancer sites. The multivalent versions of small PSMA-targeted molecules are known to be even more efficiently bound to the receptor. Here, we employ a well-known urea-based ligand, 2-[3-(1,3-dicarboxypropyl)-ureido] pentanedioic acid (DUPA) and triazine dendrimers in order to study the effect of molecular size on multivalent targeting in prostate cancer. The synthetic route starts with the preparation of a dichlorotriazine bearing DUPA in 67% overall yield over five steps. This dichlorotriazine reacts with G1, G3, and G5 triazine dendrimers bearing a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) group for Cu-labeling at the core to afford poly(monochlorotriazine) intermediates. Addition of 4-aminomethylpiperidine (4-AMP) and the following deprotection produce the target compounds, G1-(DUPA), G3-(DUPA), and G5-(DUPA). These targets include 4/16/64 DUPA groups on the surface and a DOTA group at the core, respectively. In vitro cell assay using PC3-PIP (PSMA positive) and PC3-FLU (PSMA negative) cells reveals that G1-(DUPA) has the highest PC3-PIP to PC3-FLU uptake ratio (10-fold) through the PSMA-mediated specific uptake. While G5-(DUPA) displayed approximately 12 times higher binding affinity (IC 23.6 nM) to PC3-PIP cells than G1-(DUPA) (IC 282.3 nM) as evaluated in a competitive binding assay, the G5 dendrimer also showed high non-specific binding to PC3-FLU cells. In vivo uptake of the Cu-labeled dendrimers was also evaluated in severe combined inmmunodeficient (SCID) mice bearing PC3-PIP and PC3-FLU xenografts on each shoulder, respectively. Interestingly, quantitative imaging analysis of positron emission tomograph (PET) displayed the lowest tumor uptake in PC3-PIP cells for the midsize dendrimer G3-(DUPA) (19.4 kDa) (0.66 ± 0.15%ID/g at 1 h. p.i., 0.64 ± 0.11%ID/g at 4 h. p.i., and 0.67 ± 0.08%ID/g at 24 h. p.i.). Through the specific binding of G1-(DUPA) to PSMA, the smallest dendrimer (5.1 kDa) demonstrated the highest PC3-PIP to muscle and PC3-PIP to PC3-FLU uptake ratios (17.7 ± 5.5 and 6.7 ± 3.0 at 4 h p.i., respectively). In addition, the enhanced permeability and retention (EPR) effect appeared to be an overwhelming factor for tumor uptake of the largest dendrimer G5-(DUPA) as the uptake was at a similar level irrelevant to the PSMA expression.
各种谷氨酸尿素配体对前列腺特异性膜抗原(PSMA)表现出高亲和力,PSMA 在前列腺和其他癌灶中高度过表达。已知小 PSMA 靶向分子的多价版本与受体的结合效率更高。在这里,我们使用一种众所周知的基于尿素的配体 2-[3-(1,3-二羧基丙基)-脲基]戊二酸(DUPA)和三嗪树枝状大分子,研究分子大小对前列腺癌多价靶向的影响。合成路线从制备在五个步骤中总收率为 67%的带有 DUPA 的二氯三嗪开始。这种二氯三嗪与带有 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)基团的 G1、G3 和 G5 三嗪树枝状大分子反应,在核心进行 Cu 标记,得到多(单氯三嗪)中间体。加入 4-氨基甲基哌啶(4-AMP)并随后脱保护,得到目标化合物 G1-(DUPA)、G3-(DUPA)和 G5-(DUPA)。这些靶标分别在表面具有 4/16/64 个 DUPA 基团和核心处的 DOTA 基团。使用 PC3-PIP(PSMA 阳性)和 PC3-FLU(PSMA 阴性)细胞进行的体外细胞测定表明,通过 PSMA 介导的特异性摄取,G1-(DUPA)具有最高的 PC3-PIP 与 PC3-FLU 摄取比(10 倍)。虽然 G5-(DUPA)在竞争性结合测定中对 PC3-PIP 细胞的结合亲和力(IC 23.6 nM)比 G1-(DUPA)(IC 282.3 nM)高约 12 倍,但 G5 树枝状大分子对 PC3-FLU 细胞也表现出高非特异性结合。还在分别在每个肩部携带 PC3-PIP 和 PC3-FLU 异种移植物的严重联合免疫缺陷(SCID)小鼠中评估了 Cu 标记树枝状大分子的体内摄取。有趣的是,正电子发射断层扫描(PET)的定量成像分析显示,对于中等大小的树枝状大分子 G3-(DUPA)(19.4 kDa),在 PC3-PIP 细胞中的肿瘤摄取最低(0.66±0.15%ID/g,1 h. p.i.,0.64±0.11%ID/g,4 h. p.i.,0.67±0.08%ID/g,24 h. p.i.)。通过 G1-(DUPA)与 PSMA 的特异性结合,最小的树枝状大分子(5.1 kDa)表现出最高的 PC3-PIP 与肌肉和 PC3-PIP 与 PC3-FLU 摄取比(4 h p.i.,分别为 17.7±5.5 和 6.7±3.0)。此外,增强的渗透性和保留(EPR)效应似乎是最大树枝状大分子 G5-(DUPA)肿瘤摄取的压倒性因素,因为摄取与 PSMA 表达无关。